BEAM

Beam Therapeutics Inc.

• Seeking Alpha·1d ago

  These Are The Upcoming Catalysts For Crispr Therapeutics Stock

• TipRanks·2d ago

  Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity

• TipRanks·2d ago

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• TipRanks·4d ago

  Beam Therapeutics presents Phase 1/2 data for BEAM-302

• Benzinga·4d ago

  Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference In Orlando, FL

• PUBT·4d ago

  Beam Therapeutics presents Phase 1/2 BEAM-302 AATD trial data at ATS 2026

• The Motley Fool·4d ago

  Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

• Simply Wall St·5d ago

  Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed?

• Simply Wall St·6d ago

  A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention

• TipRanks·05/14 10:15

  Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged

• Dow Jones·05/13 18:44

  Beam Therapeutics Is Maintained at Outperform by Bernstein

• Dow Jones·05/13 18:44

  Beam Therapeutics Price Target Cut to $39.00/Share From $40.00 by Bernstein

• Benzinga·05/13 18:34

  Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39

• Seeking Alpha·05/13 13:46

  Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story

• TipRanks·05/13 10:37

  Beam Therapeutics price target lowered to $39 from $40 at Bernstein